[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-febrile-illness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-febrile-illness":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100579331","phase-4-immunogenicity-and-safety-pcv-20-of-the-vaccine-administered-during-an-acute-febrile-illness-in-adults-100579331",false,"NCT06822907","Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults","Immunogenicity and Safety of the 20-Valent Pneumococcal Conjugate Vaccine (PCV-20) Administered During an Acute Febrile Illness in Adults: a Multicentric Randomized Non-inferiority Trial","PREV-HOSPIT","Inclusion criteria :\n\n* History of body temperature ≥ 38°C measured at least twice prior to randomization (Randomization must be performed as soon as possible on a febrile patient or 72 hours after apyrexia at the latest)\n* Having at least one comorbidity that defines patients as medium or high risk for pneumococcal invasive infection:\n\n  * Medium risk: Cyanogenic congenital heart disease; chronic heart failure; chronic respiratory failure; chronic obstructive pulmonary disease; emphysema; severe asthma under chronic treatment; chronic renal failure; chronic liver disease; diabetes mellitus treated; Osteo-meningeal leak or cochlear implant; Age \\> 65 years old.\n  * High risk : Hypo or asplenic people; hereditary immunodeficiency syndromes; people living with HIV; solid organ transplanted; People under immunosuppressors (corticosteroids, biotherapy) for an auto-immune or an inflammatory chronic disease; patients with nephrotic syndrome\n* Hospitalization for \\> 24 hours long\n* Social security affiliation\n* Signed informed consent\n\nExclusion criteria :\n\n* Patient unable to give informed consent\n* Curators, wardship\n* History of previous vaccination with PCV-7 or PCV-13 or PCV-20\n* History of PPV-23 in the previous year\n* Patient having received another vaccination within one month prior to inclusion or planning another vaccination in the month after inclusion except for Influenza vaccine.\n* Patient with history of bone marrow transplantation\n* Patient with haematological malignancies\n* Patient under chemotherapy for solid tumor or with a history of chemotherapy in the past three months\n* Patient treated with Rituximab currently or in the past 6 months\n* Patient with Sequential Organ Failure Assessment (qSOFA ) score ≥ 2 at randomization (acute severe febrile illness)\n* Patient hospitalized in an Intensive Care Unit\n* Pregnancy\n* Breastfeeding woman\n* Recipients of polyclonal gammaglobulins in the past three months\n* Inability to follow the protocol\n* Bleeding disorder contra-indicating intramuscular injection according to the investigator\n* History of allergy to PCV-20 or vaccine-related components.\n* S. pneumoniae infection with laboratory confirmation (blood culture, culture from a sterile site, urinary or Cerebrospinal fluid antigens, sputum culture with \\> 10\\^7 colony forming unit (CFU)\u002FmL) being the cause of the current hospitalization","ALL","18 Years","85 Years",{"count":21,"type":22},1052,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Streptococcus pneumoniae is responsible for serious infections associated to numerous hospitalizations and high rate of mortality. The incidence and therefore the burden of pneumococcal infections have been significantly reduced thanks to the use of pneumococcal conjugate vaccines (PCVs). PCVs were shown to be effective against vaccine-type serotypes causing both non-invasive and invasive pneumococcal diseases (IPD) in children and adults. PCVs use in children was shown to have an impact on IPD incidence among adults due to herd immunity and on antimicrobial resistance. To increase the protection of at-risk patients against IPD, the 20-valent PCV (PCV-20) is recently recommended in adults, after a period where PCV-13 followed by pneumococcal polysaccharide vaccine 23 valent (PPV-23) was recommended. PCV-20 effectiveness against IPD and against pneumonia was inferred from immunobridging with PCV-13. Indeed PCV-13 was shown effective to reduce the incidence of low respiratory tract infections and IPD (bacteraemia and meningitis) in 65-years-old-adults and older. Currently immunization against S. pneumoniae is recommended with PCV-20 for adult patients at-risk for IPD such as immunocompromised (=high-risk patients) and in immunocompetent people with underlying chronic conditions (cardiovascular, liver, pulmonary, kidney diseases and diabetes mellitus) (=medium risk patients). However, vaccine coverage against IPD in adults remains low globally, and does not exceed 5 % in France. Reducing missed opportunities of vaccination for S. pneumoniae is crucial.",[28,29],"Acute Febrile Illness","Pneumococcal Infections",[31,32,33,34,35,36,37],"vaccin","pneumococcal","Prevenar 20","Acute febrile illness","infections","PCV-20","PCV-21","RECRUITING","2026-03-25",{"date":41,"type":42},"2026-03-30","ACTUAL",{"date":44,"type":42},"2025-12-17",{"date":46,"type":22},"2028-10-01",{"name":48,"class":49},"Centre Hospitalier Universitaire de Saint Etienne","OTHER",24,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100410787","causes-and-outcomes-of-febrile-illness-in-health-facilities-in-rural-south-and-southeast-asia-100410787","NCT04629053","Causes and Outcomes of Febrile Illness in Health Facilities in Rural South and Southeast Asia","Determining the Causes and Outcomes of Febrile Illness in Health Care Facilities in Rural South and Southeast Asia, as Part of the South and Southeast Asian Community-based Trials Network (SEACTN). Work Package B (WP-B).","SEACTN-WP-B","Inclusion Criteria:\n\n1. The patient and\u002For where relevant their parent\u002Fguardian\u002Fcaretaker is willing and able to give informed consent \u002Fassent for participation in the study;\n2. Aged \\> 28 days (day of birth = Day 1);\n3. Axillary temperature at presentation (≥ 37.5°C (99.5°F) OR \\\u003C 35.5°C (95.9°F)) and no more likely cause than sepsis for hypothermia OR History of fever in the 24 hours prior to presentation;\n4. Onset of illness ≤ 14 days\n\nExclusion Criteria:\n\n1. Accident or trauma is the cause for the patient's presentation;\n2. Presentation ≤ 3 days after routine immunisations\n3. Is currently under follow-up or has been afebrile for less than 72 hours after completion of a follow-up period.\n4. The treating healthcare worker's decision is to send the patient home following initial assessment.","29 Days",{"count":61,"type":22},7200,"OBSERVATIONAL","This prospective multi-site observational study aims to describe causes and clinical outcomes of acute febrile illness as well as host biomarkers in patients aged \\>28 days residing in rural areas in Laos, Myanmar, Thailand, the Thai-Myanmar border region, and Bangladesh and presenting with acute febrile illnesses (≤ 14 days duration) to participating health facilities.\n\nThis study is funded by the UK Wellcome Trust. The grant reference number is 215604\u002FZ\u002F19\u002FZ",[28],[28,66,67],"Causes","Outcomes","2026-01-08",{"date":70,"type":42},"2026-01-12",{"date":72,"type":42},"2022-06-21",{"date":74,"type":22},"2026-12-01",{"name":76,"class":49},"University of Oxford",4,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":86,"sex":17,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":91,"studyType":62,"phases":4,"briefSummary":92,"conditions":93,"keywords":98,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100429936","transcriptomic-responses-for-the-identification-of-pathogens-100429936","NCT04878549","Transcriptomic Responses for the Identification of Pathogens","A Multisite Evaluation of Functional Genomic Signatures for the Improved Diagnosis of Acute Undifferentiated Febrile Infections","TRiP","FEBRILE ADULTS- INCLUSION CRITERIA\n\n* Age greater than or equal to 15 years and less than or equal to 65 years\n* Participant is willing and they and\u002For an appropriate guardian\u002Frelative\u002Frepresentative is able to give informed consent for participation in the study and a follow-up (telephone) discussion at 14 days\n* And either:\n\n  1. Febrile illness without localising features (see 'exclusion criteria' and 'screening' sections) where fever is defined as:\n\n     * documented tympanic\u002Frectal temperature of ≥ 38°C or an axillary\u002Foral temperature of ≥ 37.8°C, or a reported fever within the last 24 hours and\n     * Reported duration of fever 3-14 days or\n  2. Recently confirmed blood culture indicating enteric fever (confirmed within the previous 5 days)\n* They may have had recent exposure to antimicrobials.\n\nFEBRILE ADULTS- EXCLUSION CRITERIA\n\n* The participant may not enter the study if ANY of the following apply:\n* Unable to provide informed consent and no next of kin is willing and able to provide informed consent.\n* For patients with febrile illness (included in (1) above): Any history or clinical suspicion of:\n\n  * Rheumatological or connective tissue disorder (e.g. Rheumatoid arthritis)\n  * Autoimmune condition (e.g. Autoimmune Hepatitis)\n  * Malignancy\n  * Active treatment with immunomodulating medications, or for tuberculosis (pulmonary or extrapulmonary) or any other chronic infection.\n* Pregnancy (breast feeding mothers will NOT be excluded)\n* No hospitalisation for more than 48 hours in the last 4 weeks\n* Vaccination within 4 weeks prior to current admission\n* Localising signs or symptoms of infection sufficient to diagnose the likely cause of acute febrile illness and thus prevent it from being 'undifferentiated.'\n\nCONTROLS- INCLUSION CRITERIA\n\n* Participant is willing and they are (and in 15-18 year olds, a guardian is) able to give informed consent for participation in the study\n* Age greater than or equal to 15 years and less than or equal to 65 years\n* They live outside of the normal\u002Flocal catchment area for each hospital site\n* Afebrile (as defined by no reported fever and temperature ≤ 38°C or an axillary\u002Foral temperature of ≤ 37.8°C).\n\nCONTROLS- EXCLUSION CRITERIA\n\n* The participant may not enter the study if ANY of the following apply:\n* Unable to provide informed consent and no next of kin (or parent\u002Fguardian in the case of a minor) is willing and able to provide informed consent.\n* Current treatment for or prior history, or clinical suspicion of:\n\n  * Rheumatological or connective tissue disorder\n  * Autoimmune condition\n  * Malignancy\n  * Active treatment for tuberculosis (pulmonary or extrapulmonary) or clinical suspicion of active tuberculosis. Previous completed treatment is not a reason for exclusion.\n  * Active treatment with immunomodulating medications or any other chronic infection.\n* Pregnant (breast feeding mothers will NOT be excluded)\n* Hospitalisation within 4 weeks of recruitment\n* Vaccination within 4 weeks prior to recruitment\n* Antimicrobial use within 4 weeks of recruitment\n* Participant reports feeling more unwell than usual on the day of enrolment.\n\nEXPLORATORY AIMS- PAEDIATRIC CRITERIA; INCLUSION CRITERIA\n\n* Age greater than or equal to 2 years and less than 15 years\n* As above for adult participants.\n\nEXPLORATORY AIMS- PAEDIATRIC CRITERIA; EXCLUSION CRITERIA\n\n* Parent\u002Fguardian is unwilling, and\u002For patient aged 8 to 14 years is unwilling to assent to provide informed consent.\n* As above for adult participants.",true,"2 Years","65 Years",{"count":90,"type":22},2000,"14 Days","Acute undifferentiated febrile infection (AUFI) is a common presenting syndrome in low-resource settings and better diagnostics are urgently needed to improve patient management and guide disease prevention interventions. Assessment of the host gene expression response to infection in endemic populations has demonstrated significant promise as a new approach to identifying patients with enteric fever and for potential in differentiating between other causes of AUFI. Signatures identified through new data analytic techniques could be developed into a point-of-care test for use in endemic settings.\n\nIn this multisite diagnostic evaluation study we will collect prospective clinical, laboratory and diagnostic data from two endemic settings to evaluate host gene expression signatures for detecting enteric fever and for determining the cause of AUFI in LMIC settings.",[94,28,95,96,97],"Enteric Fever","Typhoid","Paratyphoid Fever","Fever",[99,100],"Gene Expression Profiling","RNA-Seq","2025-02-26",{"date":103,"type":42},"2025-03-03",{"date":105,"type":42},"2022-05-02",{"date":107,"type":22},"2025-06",{"name":109,"class":49},"University of Sheffield",1]